Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.98 USD
Change Today -0.19 / -8.76%
Volume 173.1K
MBII On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 5:20 PM 06/30/15 All times are local (Market data is delayed by at least 15 minutes).

marrone bio innovations inc (MBII) Snapshot

Open
$2.14
Previous Close
$2.17
Day High
$2.28
Day Low
$1.98
52 Week High
06/30/14 - $11.84
52 Week Low
05/28/15 - $1.84
Market Cap
48.3M
Average Volume 10 Days
420.3K
EPS TTM
$-2.07
Shares Outstanding
24.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MARRONE BIO INNOVATIONS INC (MBII)

marrone bio innovations inc (MBII) Related Bloomberg News

View More Bloomberg News

marrone bio innovations inc (MBII) Related Businessweek News

No Related Businessweek News Found

marrone bio innovations inc (MBII) Details

Marrone Bio Innovations, Inc. provides bio-based pest management and plant health products for the crop protection, water treatment, and other target markets in the United States and internationally. The company offers crop protection products, including herbicides for weed control; fungicides for plant disease control; nematicides for parasitic roundworm control; insecticides for insect and mite killers; and plant growth regulators, which growers use to increase crop yields, enhance plant health, manage pest resistance, and reduce chemical residues. It also provides water treatment products for invasive water pests in a range of applications comprising hydroelectric and thermoelectric power generation, industrial applications, drinking water, aquaculture, irrigation, and recreation. The company’s products include Regalia, a plant extract-based fungicidal biopesticide for plant disease control and plant health; Grandevo, a bioinsecticide for insect and mite control to the growers of specialty crops, such as grapes, citrus, tomatoes, vegetables, nuts, leafy greens, and ornamental plants; and Zequanox, a biomolluscicide that kills invasive mussels, which cause infrastructure and ecological damage primarily to power and industrial companies. Its products also include Opportune, a bioherbicide that kills weeds; and Venerate, a bioinsecticide, which kills a range of chewing and sucking insects and mites, as well as flies and plant parasitic nematodes. Marrone Bio Innovations, Inc. offers its products directly, as well as through distributors. The company, formerly known as Marrone Organic Innovations, Inc., was founded in 2006 and is headquartered in Davis, California.

151 Employees
Last Reported Date: 06/6/14
Founded in 2006

marrone bio innovations inc (MBII) Top Compensated Officers

Founder, Chief Executive Officer and Director
Total Annual Compensation: $275.8K
Compensation as of Fiscal Year 2013.

marrone bio innovations inc (MBII) Key Developments

Marrone Bio Innovations Receives Stay of Trading Suspension Pending NASDAQ Hearing

Marrone Bio Innovations, Inc. announced that it has received a letter from The NASDAQ Stock Market LLC (“NASDAQ”) indicating that a NASDAQ Hearings Panel (the “Panel”) granted the Company’s request to extend the stay of any suspension in trading in the Company’s common stock on NASDAQ at least pending the completion of the Company’s scheduled hearing before the Panel and a final determination regarding the Company’s listing status. As previously announced, as part of the Company’s request for a hearing before the Panel, the Company requested the extended stay of any suspension in trading. Also as previously announced, the hearing is scheduled for June 18, 2015. Although the Panel typically issues decisions within 30 days of the hearing date, there is no requirement that the Panel do so within that time frame. At the hearing, the Company plans to present a definitive plan to regain compliance with the NASDAQ listing rule that requires the Company to be current in the filing of its periodic financial reports with the Securities and Exchange Commission and to request an extension of time to file its delayed reports. The Panel has the discretion to grant the Company an extension to do so through November 2, 2015.

Marrone Bio Innovations, Inc. announced delayed 10-Q filing

On 05/18/2015, Marrone Bio Innovations, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

Marrone Bio Innovations Receives NASDAQ Listing Determination Letter; To Request Hearing To Seek Further Extension To File Periodic Reports

Marrone Bio Innovations, Inc. announced that on May 6, 2015, as anticipated, the Company was notified by the Listing Qualifications Staff of The NASDAQ Stock Market LLC (NASDAQ) that, based upon the Company’s continued non-compliance with NASDAQ’s filing requirements under NASDAQ Listing Rule 5250(c)(1), the uncertainty of the Company’s time frame to file all its required periodic reports and its expectation that it would not file all periodic reports with the SEC by May 13, 2015, the termination of the exception period previously granted by the Staff, the Company’s securities were subject to delisting unless the Company timely requests a hearing before the NASDAQ Listing Qualifications Panel. In addition, the Company announced that it does not expect to file on a timely basis its Quarterly Report on Form 10-Q for the three months ended March 31, 2015, resulting in further noncompliance with NASDAQ Listing Rule 5250(c)(1). The Company intends to timely request a hearing before the Panel, at which hearing the Company will present its plan to evidence compliance with NASDAQ’s filing requirement and request an extension within which to do so. In accordance with the NASDAQ Listing Rules, the Panel has the authority to continue the Company’s listing on NASDAQ pursuant to an exception to the filing requirement through as late as November 2, 2015. The Company’s common stock will continue to trade on The NASDAQ Global Market under the symbol “MBII” pending the completion of the hearing process and the expiration of any extension period granted by the Panel.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MBII:US $1.98 USD -0.19

MBII Competitors

Market data is delayed at least 15 minutes.

Company Last Change
EI du Pont de Nemours & Co $63.95 USD +0.31
Monsanto Co $106.59 USD +3.31
Sumitomo Chemical Co Ltd ¥736.00 JPY -3.00
Syngenta AG SFr.380.00 CHF -6.20
Dow Chemical Co/The $51.17 USD +0.38
View Industry Companies
 

Industry Analysis

MBII

Industry Average

Valuation MBII Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.3x
Price/Book 0.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MARRONE BIO INNOVATIONS INC, please visit www.marronebioinnovations.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.